U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 6, 2011
ONCOLOGIX TECH, INC.
(Name of Small Business Issuer as Specified in Its Charter)
|
Nevada
|
0-15482
|
86-1006416
|
|
(State or other jurisdiction of
|
(Commission File Number)
|
(I.R.S. Employer
|
|
incorporation or organization)
|
Identification No.) |
P.O. Box 8832
Grand Rapids, MI 49518-8832
(Address of principal executive offices)
(616) 977-9933
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.02. Termination of a Material Definitive Agreement
On July 6, 2011, the Pre-Incorporation Agreement, executed in February, 2011, that we had entered into with Mr. Melvin Brown, of Gilbert, Arizona was terminated because we were not successful in meeting our agreement to provide certain funding for the new “WatchMe” enterprise.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Dated: July 11, 2011
|
|
|
ONCOLOGIX TECH, INC.
|
|
|
By: /s/ Anthony Silverman
|
|
|
Anthony Silverman, President
|
|
|
By: /s/ Michael A. Kramarz
|
|
|
Michael A. Kramarz, Chief Financial Officer
|
|